Interactive Session:
261. Difficult to Treat Gram-Positives: A Case-Based Symposium
Saturday, October 29, 2016: 2:00 PM-3:30 PM
Room: La Nouvelle Orleans Ballroom

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the treatment options for infections caused by multidrug-resistant MRSA, including combination therapy
  • discuss the therapeutic approach for recalcitrant VRE infection including the role of new agents with in vitro activity
  • determine the best therapeutic approach for meningitis caused by multidrug-resistant pneumococci (case study)

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists

Tracks: Pediatric ID, Investigative ID, Epidemiology and Infection Control, Adult ID

Interactive Moderators:  Cesar Arias, MD, PhD, FIDSA, University of Texas McGovern Medical School at Houston and David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health

Presentations:
2:00 PM
Multidrug-Resistant MRSA: No Options?
Arnold Bayer, MD, FIDSA

2:25 PM
Q&A
2:55 PM
Q&A
3:00 PM
Untreatable VRE: Now What?
Truc Tran, PharmD
3:25 PM
Q&A

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-294-L01-P

Disclosures:

C. Arias, Forest/Actavis: Grant Investigator and Speaker's Bureau , Research support
Theravance: Consultant , Grant Investigator and Speaker's Bureau , Grant recipient and Speaker honorarium
Pfizer: Grant Investigator , Scientific Advisor and Speaker's Bureau , Grant recipient and Speaker honorarium
Cubist: Consultant , Grant Investigator and Scientific Advisor , Consulting fee , Grant recipient and Speaker honorarium
Bayer: Consultant and Scientific Advisor , Consulting fee
Merck: Grant Investigator and Speaker's Bureau , Research grant and Speaker honorarium
Astra-Zeneca: Speaker's Bureau , Speaker honorarium
Novartis: Speaker's Bureau , Speaker honorarium
The Medicines Company: Speaker's Bureau , Speaker honorarium

D. R. Andes, Astellas, Roche, Melinta, Actelion, Theravance, Paratek, Zavante, Scynexis: Grant Investigator , Grant recipient
Actelion, Melinta, Scynexis, Roche, Theravance, Meiji: Consultant , Consulting fee

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.